Centrose
Madison, US · Wisconsin LLC
Find your way into Centrose
Centrose develops Extracellular Drug Conjugates (EDCs), a class of antibody drug conjugate that targets the cell surfaceome by binding multiple extracellular proteins without internalization, for treating cancers such as metastatic cancers and lymphomas. Its pipeline includes EDCs aimed at drug-resistant non-Hodgkin lymphoma, metastatic cancers, and other lymphoma types.
Founders & leadership
JP
James PrudentFounder
JS
Jon S. ThorsonNamed on SEC filing
Board
HL
Hayden LeasonBoard director
RS
Raymond SchinaziBoard director
TW
Troy WilsonBoard director
Reported raises · per SEC filings
Form D private placements$1.9M disclosed across 4 rounds · 2014–2019
▶$100KraisedSep 2019 · 1 investors · PharmaceuticalsRule 506(b)
▶$100KraisedSep 2019 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James PrudentExecutive Officer, Director, Promoter
- Jon S. ThorsonDirector
- Offering amount
- $200K
- Amount sold
- $100K
- First sale
- Sep 2019
- Incorporated
- Limited Liability Company, Wisconsin
- Federal exemptions
- 06b
▶$200KraisedAug 2017 · 1 investors · PharmaceuticalsRule 506(b)
▶$200KraisedAug 2017 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jon S. ThorsonDirector
- James PrudentExecutive Officer, Director, Promoter
- Offering amount
- $1M
- Amount sold
- $200K
- Proceeds to insiders
- $210K
- First sale
- Aug 2017
- Incorporated
- Limited Liability Company, Wisconsin
- Federal exemptions
- 06b
▶$1.4MraisedJan 2016 · 3 investors · PharmaceuticalsRule 506(b)
▶$1.4MraisedJan 2016 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James PrudentExecutive Officer, Director, Promoter
- Jon S. ThorsonDirector, Promoter
- Hayden LeasonDirector
- Raymond SchinaziDirector
- Offering amount
- $21M
- Amount sold
- $1.4M
- Minimum investment
- $50K
- Proceeds to insiders
- $1.5M
- First sale
- Jan 2015
- Incorporated
- Limited Liability Company, Wisconsin
- Federal exemptions
- 06b
▶$100KraisedJan 2014 · 1 investors · PharmaceuticalsRule 506(b)
▶$100KraisedJan 2014 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James PrudentExecutive Officer, Director, Promoter
- Troy WilsonDirector
- Raymond SchinaziDirector
- Jon S. ThorsonDirector, Promoter
- Hayden LeasonDirector
- Offering amount
- $100K
- Amount sold
- $100K
- Minimum investment
- $100K
- First sale
- Jan 2014
- Incorporated
- Limited Liability Company, Wisconsin
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Greenlight Guru5 shared keywordsGreenlight Guru provides quality management, product development, and clinical evidence software built specifically for medical device companies. Its platform helps medtech teams manage compliance, design controls, risk, and clinical data collection across the product lifecycle.
Moxso5 shared keywordsMoxso provides phishing simulation and security awareness training for employees. The platform integrates simulated phishing emails and bite-sized training into daily workflows while monitoring for credential breaches and adapting content based on individual risk levels.
Medidata5 shared keywordsMedidata is a clinical trial software platform that serves pharmaceutical, biotech, and healthcare organizations conducting clinical research. It provides end-to-end trial management, patient data analytics, and regulatory compliance solutions across thousands of trials and millions of patients globally.
Companies competing with Centrose for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 8 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $224.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $199.1K |
| National Science Foundation | Phase I | 2011 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $277.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $198.8K |
| National Science Foundation | Phase ISTTR | 2008 | $75K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $244.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $163.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Centrose do?
- Centrose develops Extracellular Drug Conjugates (EDCs), a class of antibody drug conjugate that targets the cell surfaceome by binding multiple extracellular proteins without internalization, for treating cancers such as metastatic cancers and lymphomas. Its pipeline includes EDCs aimed at drug-resistant non-Hodgkin lymphoma, metastatic cancers, and other lymphoma types.
- Who founded Centrose?
- Centrose was founded by James Prudent.
- How much funding has Centrose raised?
- Centrose has disclosed $1.9M raised across 4 rounds.
- Where is Centrose headquartered?
- Centrose is headquartered in Madison, US.